blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3209311

EP3209311 - RECOMBINANT AAV VARIANTS AND USES THEREOF [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  02.02.2024
Database last updated on 17.07.2024
FormerGrant of patent is intended
Status updated on  05.10.2023
FormerExamination is in progress
Status updated on  12.05.2023
FormerRequest for examination was made
Status updated on  28.07.2017
FormerThe international publication has been made
Status updated on  08.04.2017
Most recent event   Tooltip19.07.2024Lapse of the patent in a contracting state
New state(s): BG, FI, GR, HR, RS		published on 21.08.2024 [2024/34]
Applicant(s)For all designated states
University of Massachusetts
One Beacon Street
31st Floor
Boston, MA 02108 / US
[2024/10]
Former [2017/35]For all designated states
University of Massachusetts
225 Franklin Street
Boston, MA 02110 / US
Inventor(s)01 / GAO, Guangping
4 Edward Dunn Way
Westborough, MA 01581 / US
02 / XIE, Jun
5 Fiske Street
Shrewsbury, MA 01545 / US
03 / FLOTTE, Terence
122 Paxon Road
Holden, MA 01520 / US
 [2017/35]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2024/10]
Former [2017/35]Clegg, Richard Ian, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date15852798.621.10.2015
[2017/35]
WO2015US56659
Priority number, dateUS201462066856P21.10.2014         Original published format: US 201462066856 P
[2017/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016065001
Date:28.04.2016
Language:EN
[2016/17]
Type: A1 Application with search report 
No.:EP3209311
Date:30.08.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 28.04.2016 takes the place of the publication of the European patent application.
[2017/35]
Type: B1 Patent specification 
No.:EP3209311
Date:06.03.2024
Language:EN
[2024/10]
Search report(s)International search report - published on:US28.04.2016
(Supplementary) European search report - dispatched on:EP06.07.2018
ClassificationIPC:A61K35/76, C12N15/09, C12N15/63, C12N15/86
[2017/35]
CPC:
C12N15/86 (EP,RU,US); A01K67/0275 (RU,US); A61K48/0066 (RU,US);
C07K14/005 (EP,RU,US); C12N15/113 (RU,US); C12N15/8509 (RU,US);
C12N7/00 (RU,US); A01K2217/05 (US); A01K2217/206 (US);
A01K2267/03 (EP,US); A61K35/00 (EP,US); C12N2310/113 (US);
C12N2310/141 (US); C12N2750/14121 (EP,US); C12N2750/14122 (EP,US);
C12N2750/14141 (EP,US); C12N2750/14143 (US); C12N2750/14145 (EP,US);
C12N2810/6027 (EP,US); C12N2830/008 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/35]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:REKOMBINANTE AAV-VARIANTEN UND VERWENDUNGEN DAVON[2017/35]
English:RECOMBINANT AAV VARIANTS AND USES THEREOF[2017/35]
French:VARIANTS DE VAA RECOMBINANTS ET LEURS UTILISATIONS[2017/35]
Entry into regional phase21.04.2017National basic fee paid 
21.04.2017Search fee paid 
21.04.2017Designation fee(s) paid 
21.04.2017Examination fee paid 
Examination procedure07.04.2017Date on which the examining division has become responsible
21.04.2017Examination requested  [2017/35]
01.02.2019Amendment by applicant (claims and/or description)
16.05.2023Despatch of a communication from the examining division (Time limit: M04)
12.09.2023Reply to a communication from the examining division
06.10.2023Communication of intention to grant the patent
26.01.2024Fee for grant paid
26.01.2024Fee for publishing/printing paid
26.01.2024Receipt of the translation of the claim(s)
Fees paidRenewal fee
27.11.2017Renewal fee patent year 03
29.10.2018Renewal fee patent year 04
28.10.2019Renewal fee patent year 05
27.10.2020Renewal fee patent year 06
27.01.2022Renewal fee patent year 07
28.11.2022Renewal fee patent year 08
27.11.2023Renewal fee patent year 09
Penalty fee
Additional fee for renewal fee
31.10.201703   M06   Fee paid on   27.11.2017
31.10.202107   M06   Fee paid on   27.01.2022
31.10.202208   M06   Fee paid on   28.11.2022
31.10.202309   M06   Fee paid on   27.11.2023
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipBG06.03.2024
FI06.03.2024
HR06.03.2024
LT06.03.2024
NO06.06.2024
RS06.06.2024
GR07.06.2024
[2024/34]
Former [2024/33]LT06.03.2024
NO06.06.2024
Documents cited:Search[XI]WO2006066066  (UNIV NORTH CAROLINA [US], et al) [X] 2-6,8-10,12 * figure 12; examples 1,3; claims 21, 34, 36-40, 48 * [I] 14,15;
 [E]WO2017023724  (VOYAGER THERAPEUTICS INC [US]) [E] 1-15 * SEQ ID 652 (CHt-P2) is 100% identical to SEQ ID NO: 51 of the present application;; sequence 652 *;
 [A]  - GAO GUANGPING ET AL, "Adeno-associated viruses undergo substantial evolution in primates during natural infections", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, NATIONAL ACADEMY OF SCIENCES, US, (20030513), vol. 100, no. 10, doi:10.1073/PNAS.0937739100, ISSN 0027-8424, pages 6081 - 6086, XP002255703 [A] 1-15 * abstract * * page 6083, column r, paragraph 2; figure 3 *

DOI:   http://dx.doi.org/10.1073/pnas.0937739100
 [A]  - GAO G-P ET AL, "Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, NATIONAL ACADEMY OF SCIENCES, US, (20020903), vol. 99, no. 18, doi:10.1073/PNAS.182412299, ISSN 0027-8424, pages 11854 - 11859, XP002229849 [A] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1073/pnas.182412299
 [A]  - GAO GUANGPING ET AL, "Clades of adeno-associated viruses are widely disseminated in human tissues", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, (20040601), vol. 78, no. 12, doi:10.1128/JVI.78.12.6381-6388.2004, ISSN 0022-538X, pages 6381 - 6388, XP002321999 [A] 1-15 * abstract * * figure 1; table 1 *

DOI:   http://dx.doi.org/10.1128/JVI.78.12.6381-6388.2004
 [A]  - B CHENG ET AL, "Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells", GENE THERAPY, (20110721), vol. 19, no. 4, doi:10.1038/gt.2011.105, ISSN 0969-7128, pages 375 - 384, XP055085860 [A] 1-15 * abstract * * page 5, paragraph 4 - page 6, paragraph 2 *

DOI:   http://dx.doi.org/10.1038/gt.2011.105
 [A]  - ARAVIND ASOKAN ET AL, "The AAV Vector Toolkit: Poised at the Clinical Crossroads", MOLECULAR THERAPY, (20120124), vol. 20, no. 4, doi:10.1038/mt.2011.287, ISSN 1525-0016, pages 699 - 708, XP055193366 [A] 1-15 * abstract * * page 702, column r, paragraph 4 - page 703, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.1038/mt.2011.287
 [T]  - SHAOYONG LI ET AL, "Efficient and Targeted Transduction of Nonhuman Primate Liver With Systemically Delivered Optimized AAV3B Vectors", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, US, (20151201), vol. 23, no. 12, doi:10.1038/mt.2015.174, ISSN 1525-0016, pages 1867 - 1876, XP055435148 [T] * the whole document *

DOI:   http://dx.doi.org/10.1038/mt.2015.174
International search[A]US2004101514  (LIU YUHONG [US], et al) [A] 14-16, 33-35, 38, 41, 42/(38, 41) * SEQ ID NO: 3 *;
 [XA]US2005287122  (BARTLETT JEFFREY S [US], et al) [X] 1 * para [0010], [0022], [0027], [0028], [0032], [0034], [0037], SEQ ID NOs: 21 and 22 * [A] 14-16, 33-35, 38, 41, 42/(38, 41);
 [A]US2013109742  (HEWITT CURTIS [US], et al) [A] 14-16, 33-35, 38, 41, 42/(38, 41) * SEQ ID NO: 4 *;
 [A]  - rutledge, "Adeno-associated virus 3B, complete genome", GenBank, (19980112), Database accession no. AF028705, URL: ncbi, XP055275592 [A] 14-16, 33-35, 38, 41, 42/(38, 41) * entire document *
by applicantUS5399363
 US5478745
 US5543158
 US5552157
 US5565213
 US5567434
 US5641515
 US5656016
 US5697899
 WO9810088
 US5738868
 US5741516
 US5770219
 US5779708
 US5783208
 US5795587
 US5797898
 US6001650
 US6156303
 US6177403
 US2003138772
 WO2006066066
    - K. FISHER et al., J. Virol., (19930000), vol. 70, pages 520 - 532
    - GRAHAM et al., Virology, (19730000), vol. 52, page 456
    - CHU et al., Gene, (19810000), vol. 13, page 197
    - B. J. CARTER, Handbook of Parvoviruses, CRC Press, (19900000), pages 155 - 168
    - K. FISHER et al., J Virol., (19960000), vol. 70, pages 520 - 532
    - RYAN, M D et al., EMBO, (19940000), vol. 4, pages 928 - 933
    - MATTION, N M et al., J Virology, (19961100), pages 8124 - 8127
    - FURLER, S et al., Gene Therapy, (20010000), vol. 8, pages 811 - 817
    - HALPIN, C et al., The Plant Journal, (19990000), vol. 4, pages 453 - 459
    - DE FELIPE, P et al., Gene Therapy, (19990000), vol. 6, pages 198 - 208
    - DE FELIPE, P et al., Human Gene Therapy, (20000000), vol. 11, pages 1921 - 1931
    - BOSHART et al., Cell, (19850000), vol. 41, pages 521 - 530
    - NO et al., Proc. Natl. Acad. Sci. USA, (19960000), vol. 93, pages 3346 - 3351
    - GOSSEN et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, pages 5547 - 5551
    - GOSSEN et al., Science, (19950000), vol. 268, pages 1766 - 1769
    - HARVEY et al., Curr. Opin. Chem. Biol., (19980000), vol. 2, pages 512 - 518
    - WANG et al., Nat. Biotech., (19970000), vol. 15, pages 239 - 243
    - WANG et al., Gene Ther., (19970000), vol. 4, pages 432 - 441
    - MAGARI et al., J. Clin. Invest., (19970000), vol. 100, pages 2865 - 2872
    - SANDIG et al., Gene Ther., (19960000), vol. 3, pages 1002 - 9
    - ARBUTHNOT et al., Hum. Gene Ther., (19960000), vol. 7, pages 1503 - 14
    - STEIN et al., Mol. Biol. Rep., (19970000), vol. 24, pages 185 - 96
    - CHEN et al., J. Bone Miner. Res., (19960000), vol. 11, pages 654 - 64
    - HANSAL et al., J. Immunol., (19980000), vol. 161, pages 1063 - 8
    - ANDERSEN et al., Cell. Mol. Neurobiol., (19930000), vol. 13, pages 503 - 15
    - PICCIOLI et al., Proc. Natl. Acad. Sci. USA, (19910000), vol. 88, pages 5611 - 5
    - PICCIOLI et al., Neuron, (19950000), vol. 15, pages 373 - 84
    - TAKESHI HARAGUCHI et al., Nucleic Acids Research, (20090000), vol. 37, no. 6, page e43
    - STEIN et al., J Virol, (19990000), vol. 73, pages 3424 - 3429
    - DAVIDSON et al., PNAS, (20000000), vol. 97, pages 3428 - 3432
    - DAVIDSON et al., Nat. Genet., (19930000), vol. 3, pages 219 - 223
    - ALISKYDAVIDSON, Hum. Gene Ther., (20000000), vol. 11, pages 2315 - 2329
    - WRIGHT FR et al., Molecular Therapy, (20050000), vol. 12, pages 171 - 178
    - Remington's Pharmaceutical Sciences, pages 1035 - 1038,1570-1580
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.